Chronic cough: new insights and future prospects
Chronic cough is defined in adults as a cough that lasts for ≥8 weeks. When it proves intractable to standard-of-care treatment, it can be referred to as refractory chronic cough (RCC). Chronic cough is now understood to be a condition of neural dysregulation. Chronic cough and RCC result in a serio...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2021-12-01
|
| Series: | European Respiratory Review |
| Online Access: | http://err.ersjournals.com/content/30/162/210127.full |
| _version_ | 1819283821663617024 |
|---|---|
| author | Alyn Morice Peter Dicpinigaitis Lorcan McGarvey Surinder S. Birring |
| author_facet | Alyn Morice Peter Dicpinigaitis Lorcan McGarvey Surinder S. Birring |
| author_sort | Alyn Morice |
| collection | DOAJ |
| description | Chronic cough is defined in adults as a cough that lasts for ≥8 weeks. When it proves intractable to standard-of-care treatment, it can be referred to as refractory chronic cough (RCC). Chronic cough is now understood to be a condition of neural dysregulation. Chronic cough and RCC result in a serious, often unrecognized, disease burden, which forms the focus of the current review. The estimated global prevalence of chronic cough is 2–18%. Patients with chronic cough and RCC report many physical and psychological effects, which impair their quality of life. Chronic cough also has a significant economic burden for the patient and healthcare systems. RCC diagnosis and treatment are often delayed for many years as potential treatable triggers must be excluded first and a stepwise empirical therapeutic regimen is recommended. Evidence supporting most currently recommended treatments is limited. Many treatments do not address the underlying pathology, are used off-label, have limited efficacy and produce significant side-effects. There is therefore a significant unmet need for alternative therapies for RCC that target the underlying disease mechanisms. Early clinical data suggest that antagonists of the purinergic P2X3 receptor, an important mediator of RCC, are promising, though more evidence is needed. |
| first_indexed | 2024-12-24T01:37:34Z |
| format | Article |
| id | doaj.art-c4a1e2e2a26740839b31eabe28c33b86 |
| institution | Directory Open Access Journal |
| issn | 0905-9180 1600-0617 |
| language | English |
| last_indexed | 2024-12-24T01:37:34Z |
| publishDate | 2021-12-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | European Respiratory Review |
| spelling | doaj.art-c4a1e2e2a26740839b31eabe28c33b862022-12-21T17:22:08ZengEuropean Respiratory SocietyEuropean Respiratory Review0905-91801600-06172021-12-013016210.1183/16000617.0127-20210127-2021Chronic cough: new insights and future prospectsAlyn Morice0Peter Dicpinigaitis1Lorcan McGarvey2Surinder S. Birring3 Centre for Clinical Sciences, Hull York Medical School, University of Hull, Hull, UK Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA Centre for Experimental Medicine, Dentistry, and Biomedical Sciences, Queen's University, Belfast, UK Centre for Human & Applied Physiological Sciences, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College Hospital, London, UK Chronic cough is defined in adults as a cough that lasts for ≥8 weeks. When it proves intractable to standard-of-care treatment, it can be referred to as refractory chronic cough (RCC). Chronic cough is now understood to be a condition of neural dysregulation. Chronic cough and RCC result in a serious, often unrecognized, disease burden, which forms the focus of the current review. The estimated global prevalence of chronic cough is 2–18%. Patients with chronic cough and RCC report many physical and psychological effects, which impair their quality of life. Chronic cough also has a significant economic burden for the patient and healthcare systems. RCC diagnosis and treatment are often delayed for many years as potential treatable triggers must be excluded first and a stepwise empirical therapeutic regimen is recommended. Evidence supporting most currently recommended treatments is limited. Many treatments do not address the underlying pathology, are used off-label, have limited efficacy and produce significant side-effects. There is therefore a significant unmet need for alternative therapies for RCC that target the underlying disease mechanisms. Early clinical data suggest that antagonists of the purinergic P2X3 receptor, an important mediator of RCC, are promising, though more evidence is needed.http://err.ersjournals.com/content/30/162/210127.full |
| spellingShingle | Alyn Morice Peter Dicpinigaitis Lorcan McGarvey Surinder S. Birring Chronic cough: new insights and future prospects European Respiratory Review |
| title | Chronic cough: new insights and future prospects |
| title_full | Chronic cough: new insights and future prospects |
| title_fullStr | Chronic cough: new insights and future prospects |
| title_full_unstemmed | Chronic cough: new insights and future prospects |
| title_short | Chronic cough: new insights and future prospects |
| title_sort | chronic cough new insights and future prospects |
| url | http://err.ersjournals.com/content/30/162/210127.full |
| work_keys_str_mv | AT alynmorice chroniccoughnewinsightsandfutureprospects AT peterdicpinigaitis chroniccoughnewinsightsandfutureprospects AT lorcanmcgarvey chroniccoughnewinsightsandfutureprospects AT surindersbirring chroniccoughnewinsightsandfutureprospects |